COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers
Clinical trial NCT05181683 · COMPLETED
Trial details
- NCT number
- NCT05181683
- Sponsor
- Regeneron Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-07
- Primary completion
- 2022-06-03
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.